ContraFect to Present at the Bacteriophage Therapy Summit
March 21 2019 - 6:00AM
ContraFect Corporation
(Nasdaq:CFRX), a clinical-stage biotechnology
company focused on the discovery and development of novel,
differentiated biologic therapeutics for life-threatening,
drug-resistant infectious diseases, today announced that Cara
Cassino, M.D., Chief Medical Officer and Executive Vice President
of Research and Development will participate in the inaugural
Bacteriophage Therapy Summit (“Summit”) to be held from March
25-27, 2019 in Boston, MA. Dr. Cassino was invited to the Summit to
present ContraFect’s journey to positive results in its Phase 2
clinical study with the first non-traditional antibacterial to
progress to this stage of development. She will be joined by large
pharmaceutical and biotech companies, research institutions and
technology experts, in their efforts to accelerate the clinical
development of non-traditional products such as phage and
phage-derived therapies.
Dr. Cassino will discuss the path ContraFect
forged to progress exebacase, its first-in-class, phage-derived
lysin, from the laboratory through a novel, superiority design
Phase 2 study, the first clinical trial of its kind in
antibacterials.
Presentation Details:
Title: The Pathway from Bench
to Bedside: Lysin CF-301 (exebacase) – A Case StudySession
Day & Time: Wednesday, March 27, 2019, 1:30 p.m. –
2:00 p.m. ET
Topics to be discussed include:
- Harnessing potent in vitro activity to address unmet medical
need
- Adapting traditional antibiotic development models to
non-traditional antibacterials
- Exploring the challenges and opportunities of superiority
studies – novel antibacterials warrant a novel clinical development
approach
About ContraFect:
ContraFect is a biotechnology company focused on
discovering and developing differentiated biologic therapeutics for
life-threatening, drug-resistant infectious diseases, particularly
those treated in hospital settings. An estimated 700,000 deaths
worldwide each year are attributed to antimicrobial-resistant
infections. We intend to address life threatening infections using
our therapeutic product candidates from our lysin platform and
through the use of other novel agents. Lysins are a new therapeutic
class of bacteriophage-derived, recombinantly produced,
antimicrobial proteins with a novel mechanism of action associated
with the rapid killing of target bacteria, eradication of biofilms
and synergy with conventional antibiotics. We believe that the
properties of our lysins will make them suitable for targeting
antibiotic-resistant organisms, such as Staphylococcus aureus
(“Staph aureus”) and Pseudomonas aeruginosa (“P. aeruginosa”),
which can cause serious infections such as bacteremia, pneumonia
and osteomyelitis. Our lead lysin candidate, exebacase (CF-301) is
completing a Phase 2 clinical trial for the treatment of Staph
aureus bacteremia, including endocarditis and is the first lysin to
enter clinical studies in the U.S.
Follow ContraFect on Twitter @ContraFectCorp and
LinkedIn.
Forward-Looking Statements:
This press release contains, and our officers
and representatives may make from time to time, “forward-looking
statements” within the meaning of the U.S. federal securities
laws. Forward-looking statements can be identified by words
such as “projects,” “may,” “will,” “could,” “would,” “should,”
“believes,” “expects,” “anticipates,” “estimates,” “intends,”
“plans,” “potential,” “promise” or similar references to future
periods. Examples of forward-looking statements in this release
include, without limitation, statements regarding the Company’s
ability to discover and develop novel, differentiated biologic
therapeutics for life-threatening, drug-resistant infectious
diseases, statements made regarding the Summit, including
presentation details, and ContraFect’s Phase 2 results, whether the
Company has the first non-traditional antibacterial to progress to
this stage of development, whether the Phase 2 study design was
novel and the first of its kind in antibacterials, the Company’s
ability to address life threatening infections using its
therapeutic product candidates from its lysin platform and through
the use of other novel agents, whether lysins are a new therapeutic
class of bacteriophage-derived, recombinantly produced,
antimicrobial proteins with a novel mechanism of action associated
with the rapid killing of target bacteria, eradication of biofilms
and synergy with conventional antibiotics and whether the
properties of the Company’s lysins will make them suitable for
targeting antibiotic-resistant organisms, such as Staph aureus and
P. aeruginosa. Forward-looking statements are statements that are
not historical facts, nor assurances of future performance.
Instead, they are based on ContraFect’s current beliefs,
expectations and assumptions regarding the future of its business,
future plans, strategies, projections, anticipated events and
trends, the economy and other future conditions. Because
forward-looking statements relate to the future, they are subject
to inherent risks, uncertainties and changes in circumstances that
are difficult to predict and many of which are beyond ContraFect’s
control, including those detailed in ContraFect's filings with the
Securities and Exchange Commission. Actual results may differ
from those set forth in the forward-looking statements. Important
factors that could cause actual results to differ include, among
others, our ability to develop treatments for drug-resistant
infectious diseases. Any forward-looking statement made by
ContraFect in this press release is based only on information
currently available and speaks only as of the date on which it is
made. Except as required by applicable law, ContraFect expressly
disclaims any obligations to publicly update any forward-looking
statements, whether written or oral, that may be made from time to
time, whether as a result of new information, future developments
or otherwise.
Investor Relations Contacts:
Michael MessingerContraFect CorporationTel: 914-207-2300Email:
mmessinger@contrafect.com
Lauren StivalStern Investor RelationsTel: 212-362-1200Email:
lauren.stival@sternir.com
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From Apr 2024 to May 2024
ContraFect (NASDAQ:CFRX)
Historical Stock Chart
From May 2023 to May 2024